Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Shares Sold by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC lowered its holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 21.3% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 366,554 shares of the biopharmaceutical company’s stock after selling 99,400 shares during the quarter. Los Angeles Capital Management LLC owned 0.64% of Vanda Pharmaceuticals worth $1,547,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. increased its position in shares of Vanda Pharmaceuticals by 352.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,658 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 5,186 shares during the last quarter. Raymond James & Associates acquired a new stake in Vanda Pharmaceuticals in the 4th quarter valued at approximately $42,000. Mackenzie Financial Corp purchased a new stake in Vanda Pharmaceuticals in the fourth quarter valued at approximately $46,000. Sherbrooke Park Advisers LLC acquired a new position in Vanda Pharmaceuticals during the third quarter worth $52,000. Finally, New York State Common Retirement Fund boosted its position in shares of Vanda Pharmaceuticals by 57.1% during the third quarter. New York State Common Retirement Fund now owns 17,805 shares of the biopharmaceutical company’s stock worth $77,000 after buying an additional 6,470 shares during the period. Hedge funds and other institutional investors own 88.14% of the company’s stock.

Analyst Upgrades and Downgrades

VNDA has been the topic of several research reports. TheStreet lowered Vanda Pharmaceuticals from a “c-” rating to a “d” rating in a research note on Thursday, February 8th. StockNews.com cut shares of Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, April 22nd.

Vanda Pharmaceuticals Stock Performance

Shares of Vanda Pharmaceuticals stock opened at $5.48 on Wednesday. The business has a 50-day simple moving average of $4.34 and a 200-day simple moving average of $4.10. The company has a market cap of $318.93 million, a PE ratio of 109.60 and a beta of 0.71. Vanda Pharmaceuticals Inc. has a one year low of $3.30 and a one year high of $6.98.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings results on Wednesday, February 7th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.05. The firm had revenue of $45.27 million during the quarter, compared to the consensus estimate of $37.00 million. Vanda Pharmaceuticals had a return on equity of 0.46% and a net margin of 1.30%. On average, sell-side analysts predict that Vanda Pharmaceuticals Inc. will post -0.06 earnings per share for the current fiscal year.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.